nestle glp 1 food to launch Vital Pursuit frozen for GLP-1 users Nestlé Health Science Launches Comprehensive
Description
He cautions that the evidence is early and requires validation with well-designed, controlled trials
In May 2022, the U.S
NICE for early-onset T2D and obesity
Fifty-two injections per year instead of 365
A 20% relative risk reduction in MACE, including myocardial infarction, stroke, and cardiovascular death and a 30% relative risk reduction in hospitalizations for HF (58)
In fact, GLP-1 agonists are the fastest growing class of diabetes medicines with a 36% five-year compound annual growth rate and accounting for 16% of prescriptions in 2023
